Abstract: Alzheimer's disease (AD) is an age-related neurodegenerative disorder. The pathology of AD includes amyloid-β (Aβ) deposits in neuritic plaques and neurofibrillary tangles composed of hyperphosphorylated tau, as well as neuronal loss in specific brain regions. Increasing epidemiological and functional neuroimaging evidence indicates that global and regional disruptions in brain metabolism are involved in the pathogenesis of this disease. Aβ precursor protein is cleaved to produce both extracellular and intracellular Aβ, accumulation of which might interfere with the homeostasis of cellular metabolism. Mitochondria are highly dynamic organelles that not only supply the main energy to the cell but also regulate apoptosis. Mitochondrial dysfunction might contribute to Aβ neurotoxicity. In this review, we summarize the pathways of Aβ generation and its potential neurotoxic effects on cellular metabolism and mitochondrial dysfunction.
Introduction
Alzheimer's disease (AD) is one of the most common forms of neurodegeneration, characterized by extracellular accumulation of neurotoxic amyloid-β (Aβ) peptide, intracellular hyperphosphorylated tau, and loss of synapses and neurons. Aβ precursor protein (APP), conservatively expressed in many types of mammalian cells, is a type I transmembrane glycoprotein [1] . Both upregulated production and deficient removal result in Aβ accumulation. Aβ accumulation in the brain is a key event in the development of AD, resulting in cellular oxidative stress and tau hyperphosphorylation [2] . Therefore, Aβ is considered to be a central molecule and plays a key role in the development of AD. The pathological process of Aβ neurotoxicity, however, is not well known.
Increased protein oxidation and decreased cellular reduction are hallmarks of aging and age-related degenerative processes. Metabolic deficiency, especially in energy, as well as up-regulated oxidative stress, is critical to the development of AD pathology [3, 4] . Increasing evidence shows decreased glucose absorption and abnormal glucose metabolism in the brains of AD patients [5, 6] . In specific regions like the temporo-parietal and posterior cingulate cortex, an increased amyloid burden is coupled with decreased metabolism [7] . Generally, in the context of global cellular energy, the levels of glucose metabolism and ATP are remarkably decreased in AD patients [3, 8, 9] . A decrease of energy metabolism in the brain might contribute to the neuronal loss and cognitive decline in AD. metabolism and ATP production, such as the respiratory chain complex and ATP synthase [9, 10] , might be expressed abnormally and alter enzymatic activity in the pathological process leading to AD. Oxidative modification of these proteins contributes to their decreased enzymatic activity.
The oxidative modification and subsequent inactivation of glycolytic enzymes may result in a substantial decline in cellular metabolism, further inducing mitochondrial dysfunction, and resulting in the release of key factors leading to mitochondrial damage-related apoptosis. Increasing evidence indicates that AD pathology is correlated with mitochondrial dysfunction, including autophagy, fissionfusion dynamics, and biogenesis [11, 12] . In this review, we summarize the pathways of Aβ generation and its potential neurotoxic effects causing cellular metabolic deficiency and mitochondrial dysfunction.
2 Aβ production and molecular interactions 2.1 Profiles of APP cleavage Aβ is considered to play a central and key role in the development of AD. Aβ aggregation in neuritic plaques incurs oxidative neuronal damage, neurofibrillary tangles, and loss of hippocampal neurites and synapses [2] . APP belongs to the type I transmembrane protein family. In humans, the AβPP gene contains 18 exons, of which exons 7, 8 and 15 are alternatively spliced to produce at least 8 splice variants of AβPP mRNA. APP695, APP751 and APP770 are the predominant transcript proteins [1] . APP is known to modulate neuronal responses, such as neuritic growth and synaptic generation and plasticity. Aβ production from APP is a key event for the physiological function of APP and the pathological process underlying AD. Full-length APP770
is cut by α-secretase between amino-acids 687 and 688 in the α-cleavage pathway; the P3 fragment, not Aβ, is derived from APP when γ-secretase cleaves the remaining C83 fragment. However, APP is cut by β-secretase between amino-acids 671 and 672 and by γ-secretase in the transmembrane domain in the Aβ pathway; Aβ peptides of different lengths (39-43 amino-acids) are generated, depending on the site of cleavage by γ-secretase (Fig.   1A ). In terms of subcellular structure, however, a question remains over where Aβ is generated. There are three potential means of Aβ production (Fig. 1B) . First, Aβ is thought to be shed from the cell surface, based on the facts that APP is an integral membrane protein and that Aβ-rich senile plaques are deposited extracellularly. Second, Aβ is considered to be generated in an endosomal/lysosomal pathway [13] [14] [15] [16] . Third, Aβ is suggested to be produced in the endoplasmic reticulum (ER) and Golgi apparatus/transGolgi network [17] [18] [19] , but this needs to be confirmed. [20] , and other integrins [21] .
Cell surface proteins binding to Aβ
However, the specific receptors binding to Aβ are still under investigation. The binding of Aβ to receptors may induce trafficking, endocytosis, or phosphorylation of the intracellular domain of receptors, resulting in a subset of cell signals in response to oxidative stress and cellular metabolism.
Intracellular Aβ accumulation Intracellular Aβ has
been found in transgenic mice overexpressing mutant human APP and in brains from patients with AD and Down's syndrome [22] [23] [24] . Intracellular Aβ is increasingly suggested to participate in pathological processes leading to AD. It is present in AD-affected areas of the brain and seems to appear prior to neurofibrillary tangles and senile plaques [25] .
Both intracellular cleavage of APP and Aβ internaliza-
tion from the extracellular milieu result in its intracellular accumulation [26] . Synaptic loss is a pathological correlate of the cognitive impairment in AD and synaptic dysfunction is considered to be the earliest event in the development of AD. Recently, it was suggested that intracellular
Aβ is linked to synaptic activity, and that synaptic activity responds to the intracellular Aβ product [27] . On one hand, synaptic activity is suggested to decrease intracellular secretion of Aβ, which protects synapses [28] . On the other hand, intracellular Aβ accumulation results in a deficit in long-term synaptic plasticity [29, 30] .
Accumulation of Aβ in intracellular compartments
has been demonstrated in the ER, Golgi apparatus, and mitochondria [31, 32] . Mitochondria, the organelles that generate energy for the cell, play important roles not only in regulating energy metabolism but also in signaling, including cellular differentiation and apoptosis-programmed cell death. Increasing evidence supports the concept that mitochondrial dysfunction is involved in the ageing process and the pathology of AD and mitochondrial dysfunction occurs early in AD [33] .
Aβ and mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) ABAD, first identified in 1997 by Yan et
al. using a yeast two-hybrid screen [34] , is the best character- it was found to also reside in mitochondria [35] . The traffic of ABAD between the ER and mitochondria may be important for cell survival. ABAD might play important roles in cellular metabolic homeostasis and in response to mitochondrial stress [36] . Recent studies indicate that Aβ and ABAD are co-localized to mitochondria as visualized by electron microscopy and they co-immunoprecipitate from a mitochondrial preparation. Aβ may interact directly with the mitochondrial enzyme ABAD [37] . Binding of Aβ to ABAD distorts the structure of the enzyme. The structural relationships of Aβ and ABAD show that Aβ binds to ABAD in such a way as to exclude NAD + binding, which is needed in its enzymatic action [37] . The Aβ-ABAD interaction inactivates the metabolic properties of the enzyme and promotes the mitochondrial generation of free radicals. In APP/Presenilin double-transgenic mice, the level of ABAD is increased in an Aβ-rich environment and the mice demonstrate accelerated formation of senile plaques and a decline in spatial learning/memory [36] . Inhibition of the Aβ-ABAD interaction, however, reduces mitochondrial Aβ accumulation and improves mitochondrial function [38] .
Therefore, intracellularly accumulated Aβ may be a factor in the metabolic deficit and in the generation of mitochondrial reactive oxygen species, leading to oxidative cellular damage.
Oxidative stress and mitochondrial dysfunction
Increasing evidence has supported the concept that accumulated Aβ induces wide oxidative cellular damage, including modified products of nucleic acids [39, 40] (e.g.,
8-hydroxydeoxyguanosine and 8-hydroxyguanosine) and
proteins (e.g., 3-nitrotyrosine and protein carbonyls), as well as products of lipid peroxidation [41] [e.g., 4-hydroxynonenal (HNE), F2-isoprostane and malondialdehyde], protein oxidation [42] and glycoxidation [43] (e.g., carboxymethyllysine and pentosidine). The level of oxidative stress is elevated in cells cultured with Aβ in vitro and in the brains of transgenic APP animals and AD patients.
Oxidation of lipids, proteins and DNA Lipid per-
oxidation is considered to occur early in the pathogenesis of AD and it has two outcomes: structural damage of membrane integrity and the generation of α,β-unsaturated aldehydic by-products including HNE and acrolein. Both HNE and acrolein are elevated in vulnerable brain regions of subjects with mild cognitive impairment [44] , preclinical AD [45] , and late-stage AD [46, 47] . The lipid oxidation by-product HNE may cause protein oxidation and form HNE-protein adducts; therefore the activity of enzymes involved in energy metabolism, such as glucose transporters and ATP synthase, would decrease [48, 49] . However, HNE modification of nicastrin, a key subunit of γ-secretase, is suggested to enhance binding to its substrate and to increase γ-secretase activity [50] . Acrolein not only interacts with NAD + to decrease the production of NADH, but also inhibits the enzymatic activity of NADH-linked mitochondrial pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, resulting in down-regulation of energy metabolism in the TCA cycle [51] .
Increasing and considerable evidence suggests that oxidative damage to DNA begins with mild cognitive impairment and is associated with AD [52] . However, the ability to repair DNA is deficient in neurodegenerative conditions, including AD [53] . The levels of the DNA repair-related proteins Rad50, Mre11 and Nbs1 in the Mre 11 DNA-repair complex are significantly decreased in AD neocortex compared to age-matched controls [53] . Attack by free radicals can lead to strand breaks, DNA-DNA and DNA-protein cross-interactions, and the formation of base adducts. The α,β-unsaturated aldehydic by-products of lipid peroxidation, including HNE and acrolein, can interact with DNA bases leading to the formation of bulky exocyclic adducts.
Oxidative damage of mitochondrial DNA (mtDNA) is dramatically increased in AD brains [54] . and the organization of cristae (fragmentation) are substantially changed in AD [55] . Unlike nuclear DNA, mtDNA is sensitive to oxidative damage due to failure of protection by histones or DNA-binding proteins and in the repair of mtDNA in the central nervous system. In specimens from autopsied AD patients, mitochondrial mass including mtDNA is reduced while mtDNA fragmentation is increased [56] . This damage is correlated with oxidative mitochondrial damage.
Mitochondrial damage and apoptosis
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Mitochondrial abnormality is a key factor in apoptosis [57] [58] [59] . Increasing evidence has indicated that Aβ in- 
Cellular metabolic deficiencies
Cellular metabolic dyshomeostasis An extensive imbalance of cellular metabolism is implicated in AD
pathology. Based on the assessment of regional hypometabolism by imaging studies using positron emission tomography with 18 F-fluorodeoxyglucose, a pattern of bilateral temporo-parietal hypometabolism, especially associated with dementia, is considered to be a characteristic of AD [60] . Further, based on the results of 1 H NMR spectroscopy, there is a decrease in N-acetyl-L-aspartate, glutamate, glutamine, taurine (except in the hippocampus), γ-amino butyric acid (except in the frontal cortex), choline and phosphocholine, creatine and phosphocreatine, and succinate in the hippocampus, cortex, frontal cortex, and midbrain of transgenic AD mice. However, the concentrations of lactate, aspartate, glycine (except in the midbrain), alanine (except in the frontal cortex), leucine, iso-leucine, valine and water-soluble free fatty-acids are increased [61] .
In the frontal cortex of postmortem AD brains, the concentration of lactate is also increased but the pH and activity of pyruvate dehydrogenase are suggested to decrease [62] .
In the cerebrospinal fluid of AD patients, lactate is also increased, but succinate, fumarate, and glutamine are decreased [63] . These findings indicate that cellular metabolism is disturbed in AD.
Energy metabolism
In terms of global cellular energy, the levels of glucose metabolism and ATP are remarkably decreased in AD patients [3, 8] . 
NAD
+ /NADH NAD + and NADH are involved in glycolysis, the TCA cycle, and oxidative phosphorylation.
Under physiological conditions, the ratio of free NAD + / NADH in the cytosol is about 700 to 1 [64, 65] and they regulate glycolysis by acting as cofactors for the glycolytic enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
While the ratio of mitochondrial free NAD + /NADH is about 7 to 1 [64] , NAD + and NADH are also key mediators of the mitochondrial TCA cycle and oxidative phosphory- shuttle. The malate-aspartate shuttle is considered to be predominant in neurons [66] . that Aβ suppresses cellular energy metabolism [67] . (Grp78), an ER chaperone protein, has been demonstrated to bind APP [68] . ER stress could alter the localization of APP from late to early compartments of the secretory pathway and decrease Aβ production [69] . Lactic acidosis is implicated in ER stress responses. Therefore, lactate is suggested to enhance APP interaction with Grp78, leading to aberrant APP processing with increased generation of Aβ [63] .
Lactate
GAPDH GAPDH (Enzyme Commission number
1.2.1.12), known for its role in glycolytic metabolism, is one of the abundantly expressed oxidoreductases and comprises 10%-20% of total cellular protein [70] . Besides glucose metabolism, GAPDH participates in several nonmetabolic processes, including transcription activation [71] , initiation of apoptosis [72] , and ER-to-Golgi vesicle shuttling [73] . Glycolytic GAPDH is a homologous tetramer stress, GAPDH undergoes oxidative modifications, which may influence its structure and enzymatic activity [74] .
Since oxidative stress and damage are major features of AD pathology, decreased activity may contribute to the hypometabolism in AD etiology. Decreased dehydrogenase activity of cerebral GAPDH has been reported in both transgenic mice (Tg2576) and in animal models receiving hippocampal injections of Aβ [75] . Increased disulfidelinked GAPDH has been reported in AD brains and aged transgenic AD mice [76] , and detergent-insoluble GAPDH is further found to co-localize with neurofibrillary tangles in the AD brain [77] . The cytoplasmic domain of APP is suggested to interact with GAPDH and regulate cellular energy metabolism [78] . However, non-glycolysis-related forms of GAPDH are suggested to bind Aβ. Native tetrameric GAPDH does not interact with soluble Aβ, but nonnative forms, including that induced by cold denaturation, unfolding in guanidine hydrochloride, and modification by oxidation, bind to soluble but not aggregated Aβ [79] . [10, 80, 81] . At the mRNA level, the transcription of mitochondrial genes encoding cytochrome b (a component of complex III), COX subunit 1 (complex IV) and the ATPase δ-subunit is increased in brain sections from AD patients compared with control subjects; transcription of the mitochondrial gene encoding the NADH 15-kDa subunit (complex I), however, is decreased [82] . Over-expression of these mitochondrial genes might be a result of functional compensation for the depression of enzymatic activity. with controls [12] . This finding also suggests reduced mitochondrial biogenesis in AD. Activation of the PKA/CREB pathway is suggested to rescue the deficiency in mitochondrial biogenesis [12] .
Mitochondrial biogenesis
Conclusion and perspective
In conclusion, increasing evidence suggests that 
